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INTRODUCTION 
Stroke is becoming an important cause of pre-mature death and 
disability in developing countries. In India, the Incidence rate is 119-
145/100,000 population1. The poor are increasingly affected by stroke, as they 
are not being able to afford the high cost for stroke care. Majority of stroke 
patients continue to live with the disability and the huge financial burden 
undertaken by the family members, impoverish their families. In a country with 
social disparities in access to medical care, the management aspects and 
rehabilitation measures of this disease in the public sector is of vital 
importance. 
A stroke or cerebrovascular accident is defined by sudden onset of 
neurological deficit that is attributable to a focal vascular cause. Clinical 
manifestations of stroke are highly variable because of the complex anatomy of 
the brain and its vasculature. When the blood flow is quickly restored, brain 
tissue can recover fully and the symptoms are only transient, this is termed as 
transient ischemic attack (TIA). But when the blood flow cannot be quickly 
restored, irreversible brain damage occurs, resulting in ischemic stroke. 
Rupture of cerebral blood vessels, leads to leakage of blood into the brain 
parenchyma resulting in hemorrhagic stroke, which constitutes 15% of all 
stroke cases and carries higher mortality rate. 
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Neutrophil to lymphocyte ratio (NLR) is a effortless and basic parameter 
that is readily obtained from the complete blood count, even in peripheral 
hospitals. Inflammation is regarded as a set of interactions between and among 
immune related cells such as lymphocytes, neutrophils which in turn lead to 
killing of tissues and destruction which is going on in stroke. One of the 
inflammatory markers in stroke is NLR and also has its relationship between 
many disease like, myocardial infarction, COPD, chronic renal failure, etc., 
 In this study the association that occurs between NLR and stroke is 
found out which help to assess the morbidity and mortality of stroke, as NLR is 
easy obtainable investigation and low cost one. 
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OBJECTIVES OF OUR STUDY 
 
1. To study the clinical presentation and risk factors of acute stroke. 
2. To study the pattern of stroke and neutrophil lymphocyte correlation. 
3. To follow up the patient for 30 days to know the mortality. 
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REVIEW OF LITERATURE 
 
BLOOD SUPPLY OF BRAIN      
 Brain gets its arterial supply from 2 pairs of vessels. The vertebral 
arteries which forms the posterior circulation  and internal carotid arteries 
which forms the anterior circulation. Both are interconnected in cranial cavity 
and produce Circle of Willis. 
 Anterior cerebral circulation 
The Internal carotid artery is the branch of common carotidartery. They 
proceed superiorly enter in to the cranial cavity through carotid canal. By 
entering the cranial cavity each of the internal carotid artery gives off  the 
anterior cerebral artery, the middle cerebral artery, the posterior 
communicating artery and the ophthalmic artery. 
Anterior cerebral artery supplies the entire medial surface of cerebral 
hemisphere including a strip of cortex for about 2 cm along the superolateral 
surface and medial half of orbital surface except the occipital lobe. Recurrent 
artery of Heubner is an important branch ofACA and its involvement causes 
faciobrachial monoplegia. 
Middle cerebral artery supplies the entire lateral surface of cerebrum 
including lateral half of orbital surface except, frontal pole and a strip of cortex 
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for about 2 cm along superolateral surface of frontal lobe, medial half of orbital 
surface, lower temporal and occipital pole. 
Posterior cerebral artery supplies the medial surface of temporal and 
occipital lobes and their tentorial surface. It also supplies cerebellum, medulla, 
pons, midbrain, subthalamus and thalamus. 
 
FIGURE 1 - BLOOD SUPPLY BY MCA 
 Posterior cerebral circulation 
Vertebral arteries  
Vertebral artery arises from first part of subclavian artery enters the 
cranial cavity through foramen magnum, each vertebral artery gives small 
meningeal branch. Vertebral artery gives 3 additional branches: 
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1. Anterior spinal artery 
2. Posterior spinal artery 
3. Posterior inferior cerebellar artery. 
Vertebral artery on each side joins to form basilar artery. Its branches in  
caudal to rostral direction anterior inferior cerebellar arteries, several small 
pontine arteries,superior cerebellar arteries. Basilar artery bifurcates into 
posterior cerebral arteries. 
CIRCLE OF WILLIS 
Cerebral arterial circle is formed at the base of the brain by the 
interconnecting vertebrobasilar and internal carotid systems of arteries. 
 
FIGURE 2 -  CIRCLE OF WILLIS 
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This interconnections achieved by an anterior communicating artery 
which interconnects left and right anterior cerebral arteries, 2 posterior 
communicating arteries one on each side connects posterior cerebralartery with 
the internal carotid artery. 
INTERNAL CAPSULE 
 
FIGURE 3: INTERNAL CAPSULE: 
The anterior limb of internal capsule is bounded medially by the head of 
the caudate nucleus and laterally by the lentiform nucleus. Genu of the internal 
capsule lies at the most medial edge of the globuspallidus Posterior limb of 
internal capsule is bounded medially by the thalamus and laterally by the 
lentiform nucleus. Corticonuclear fibers which are motor fibers from the 
cerebral cortex to the motor nuclei of the cranial fibers pass through the genu of 
internal capsule. Corticospinal fibers pass through the anterior two third of the 
posterior limb of the internal capsule. Genu and posterior limb of the internal 
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capsule is supplied by the striate branches of the anterior and middle cerebral 
arteries. 
WHO DEFINITION OF STROKE 
 
FIGURE 4 – ISCHAEMIC & HEMORRHAGIC STROKE 
Rapidly developing clinical symptoms or signs of focal or global loss of 
cerebral function with symptoms lasting for more than 24hrs or leading to 
death with no apparent cause other than that of vascular origin2. 
TYPES OF STROKE  
Types 
o Subdural epidural hemorrhage Produced by trauma 
o Subarachnoid hemorrhage Due to trauma or rupture ofintracranial 
aneurysm 
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o Intraparenchymal hemorrhage 
INTRAPARENCHYMAL HEMORRHAGE 
 Most common type Intracerebral hemorrhage 
Causes 
o Hypertension 
o Trauma 
o Cerebral amyloid angiopathy 
o Cocaine and amphetamine use in young 
o Coagulopathy 
o AV malformation 
o Metastatic brain tumor 
ISCHEMIC STROKE 
ETIOLOGY 
 Thrombosis 
o Large vessel thrombosis 
o Lacunar stroke (small vessel) 
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o Dehydration 
 Embolic occlusion 
Artery to artery: 
o Carotid bifurcation 
o Aortic arch 
o Arterial dissection 
Cardioembolic: 
o Atrial fibrillation 
o Mural thrombus 
o Myocardial infarction 
o Dilated cardiomyopathy 
o Valvular lesions :Mitral stenosis 
o Mechanical valve 
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ISCHEMIC STROKE 
PATHOPHYSIOLOGY OF ISCHEMIC STROKE AND CEREBRAL 
BLOOD FLOW 
Normal cerebral perfusion is about 50-60 ml/100g/min. The effects of 
brain ischemia are rapid as there is no stored glucose and neurons are in 
capable of anaerobic metabolism. In response to ischemia, cerebral 
FIGURE 5 CARDIOGENIC EMBOLI ORIGIN 
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autoregulatory mechanisms come into play by local vasodilatation, opening of 
collaterals and increased utilisation of oxygen and glucose from blood.  
A decrease in cerebral perfusion to zero leads to death of brain tissue 
within 4-10minutes. A decrease to less than 10 ml/100g/min culminates in 
irreversible neuronal injury. A decrease to less than 16-18ml/100/min results in 
infarction within an hour. 
When cerebral blood flow decreases to less than 20ml/100g/min, an 
electrical silence ensues with a decrease in synaptic activity in an attempt to 
preserve energy stores. This results in ischemia without infarction unless this 
situation is extended for several hours or days. 
If reperfusion occurs prior to significant amount of cell death, there may 
be only transient symptoms and this is referred to as Transient Ischemic Attack 
(TIA). The standard definition of TIA requires all the neurological signs and 
symptoms to resolve within 24 hours regardless of whether there is imaging 
evidence of new permanent brain injury. 
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A generalized reduction in cerebral blood flow due to systemic 
hypotension usually causes syncope. If the low blood flow persist long persists 
longer, infarction develops in the border zone of major artery territories. Severe 
global hypoxia ischemia causes extensive brain injury referred to as Hypoxic 
Ischemic Encephalopathy. 
FOCAL ISCHEMIC INJURY 
Vascular occlusion by thrombus or embolus can cause ischemia of 
affected vascular territory. At gross tissue level, vascular compromise causes 
acute ischemia or infarction which is a dynamic process evolving causes acute 
ischemia over time. At cellular level, hypoxia causes neuronal injury. 
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NEURONAL INJURY 
Ischemia triggered activation of destructive vasoactive enzymes released 
by endothelium, leucocytes, platelets and other neuronal cells promote the 
formation of micro thrombus which includes the cerebral micro circulation". 
At molecular level, occurrence of hypoxic ischemic neuronal injury is 
mainly influenced by the over action of neurotransmitters glutamate and 
aspartate. This process is called excitotoxicity. It is triggered by depletion of 
cellular energy stores. Glutamate is normally stored in synaptic terminals. It is 
cleared from the extracellular space by an energy dependent process. 
Hence in an energy depleted state, there is an higher concentration of 
glutamate and aspartate in the extracellular space. This causes the opening of 
calcium channels associated with N-Methyl-DA separate (NMDA) and Alpha-
Amino-3-Hydroxy-3-Methyl-4-Isoxanolepropionate (AMPA) receptors. 
Persistent membrane depolarization results in influx of calcium, sodium and 
chloride ions and efflux of potassium ions. Increased intracellular calcium 
induces activation of destructive enzymes like proteases, lipases and 
endonucleases. These permit the release of cytokines and other mediators 
which end up destroying the cellular integrity.  
Inflammatory response to tissue injury is mediated by various 
inflammatory mediators among which Tumour Necrosis Factor is the key 
agent. Leucocyte recruitment to ischemic areas occurs within 30 minutes of 
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ischemia and reperfusion. Leucocytes activate vasoactive substances like 
oxygen free radicals, arachidonic acid metabolites and nitric acid.  
These cause vasodilatation, vasoconstriction, more permeability, 
enhanced platelet aggregation, increased leucocyte adhesion to the endothelial 
wall and immuno regulation. 
First to respond to hypoxia are endothelial cells. The response is 
morphological, biochemical and immunological causing a variety of 
physiological and pharmacological effects. Endothelial cells swell and form 
microvilli on the luminal surface. This causes a narrowing of luminal patency 
of capillary vessels. As a result, mechanical plugging by erythrocytes, 
leucocytes and platelets ensues. Endothelial cells mediate the effects of 
vasoactive agents like endothelin peptides, eicosanoids and smooth muscle 
relaxants such as nitric acid. These agents alter vascular tone of the 
microcirculation. The key process in the initiation of the inflammatory process, 
namely leucocyte adherence to the endothelial wall, is brought about by 
activation of endothelial adhesion molecules. 
ISCHEMIC PENUMBRA 
Within an hour of hypoxic ischemic insult, an oligemic zone called 
ischemic penumbra develops around a core of infarction, where the auto 
regulation is ineffective. In this area, cellular integrity and some amount of 
energy metabolism is preserved. Neurological deficits due to ischemia in this 
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region can be partially or fully reversed by reperfusing within a critical time 
period (2-4hrs) called the Window period. 
Pathophysiology of ischemic penumbra is closely related to generation 
of Spontaneous Waves of Depolarisation (SWD). These are multifocal in 
origin, some arising from the core of infarction, some from the penumbra. They 
are associated with sustained increase in synaptic glutamate and extracellular 
potassium". Hypoxic rapid depolarizations supervene just before irreversible 
neuronal death.3 
NEURONAL DEATH 
Occurs by 2 processes. Coagulation necrosis and Apoptosis. Apoptotic 
mechanisms start within an hour of ischemic injury whereas necrosis sets in 
about 6hours after arterial occlusion. 
COAGULATION NECROSIS 
Rapid breakdown of cellular cytoskeleton principally due to energy 
failure. Attributed to effects of physical, chemical and osmotic damage to 
plasma membrane. Cell initially swells, then shrinks and undergoes pyknosis 
over 6-12hrs. By 24hours, extensive chromolysis occurs resulting in pan 
necrosis. Astrocytes swell and fragment, myelin sheath degenerates". 
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APOPTOSIS 
In this, cells are programmed to die. Nuclear damage is the first to 
occur. Integrity of plasma membrane and mitochondrial membrane are 
preserved till the last. Ischemia causes activation of latent suicide proteins in 
the nucleus which triggers the autolytic processes culminating in cell death. 
This autolytic process involves DNA cleavage. 
Ischemia starves the neuron of glucose and oxygen leading to failure of 
mitochondria to produce ATP. In the absence of ATP, membrane ion pumps 
stop functioning leading to depolarization of neurons and increase in 
intracellular calcium. Cellular depolarization causes increased glutamate 
release from the synaptic terminals. Excess glutamate activates postsynaptic 
glutamate receptors which enhance neuronal calcium influx resulting in 
neurotoxicity. Free radicals formed by membrane lipid degradation and 
mitochondrial dysfunction result in catalytic destruction of the membrane and 
damage other vital functions of the cell. 
Progression and extent of ischemic injury depends on 
i. Rate of progression and onset : Short duration and slow onset stroke are 
better tolerated. 
ii. Collateral circulation :Good collateral circulation correlates with better 
outcome 
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iii. Health of systemic circulation: Constant cerebral perfusion pressure 
depends on adequate systemic blood pressure 
iv. Hematological factors: Hypercoagulable state causes exacerbation of 
vascular occlusion by increasing progression and extent of thrombus 
v. Temperature : Increased temperature causes greater ischemic Injury 
vi. Glucose metabolism : Hyperglycemia adversely affects size of Infarct 
RISK FACTORS FOR STROKE 
1. Gender 
 Male gender increases the risk for stroke4. Men has 1.3times higher risk 
for stroke than female except in the highest ages. Difference in the risk between 
the gender disappears at high age over 80-85 years. The gender risk is different 
for subarachnoid haemorrhage where the risk is higher for women. 
2. Age  
Incidence of stroke increases with age in both men and women5. This 
increased stroke incidence is seen in ischaemic as well as for intracerebral 
haemorrhage, subarachnoid haemorrhage. The risk of stroke more than doubles 
with each decade of increased age after 55 years of age. 
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3. Ethnicity 
African origin people have higher risk than Caucasians. This can be 
explained by the poor management of treatable risk factors. The proportion of 
intracerebral haemorrhage is higher in Chinese than Caucasians. In ischaemic 
stroke, the prevalence of intracranial artery stenosis is more frequent in East 
Asians and African Americans than in Caucasians6. 
4. Genetic causes 
Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leuko encephalopathy (CADASIL-notch-3 gene),cerebral autosomal recessive 
arteriopathy and leuko encephalopathy (CARASIL-HTRA gene). 
MELAS(mitochondrial myopathy encephalopathy, lactic acidosis, and stroke 
like episodes), homocystinuria, Fabry disease(alphagalactosidase gene), Ehlers-
Danlos syndrome type IV, Marfansyndrome, pseudoxanthoma elasticum, 
HANAC(hereditaryangiopathy, nephropathy, aneurysm, and muscle cramps 
syndrome;COL4A/ mutation)7. All these above mentioned syndrome has stroke 
or stroke like episode as one of the feature of the different clinical 
manifestation. Sickle cell anemia increases the incidence of stroke in 
childhood"8. Increased transcranial ultrasound velocities of the middle cerebral 
artery has increased risk in sickle cell anemic children. Single nucleotide 
polymorphism in the chromosome 9p21 associated with ischemicstroke"9, 
single nucleotide polymorphism in HDAC9 on chromosome 7p21.1 also 
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associated with ischemic stroke10. The APOE epsilon2&4 are related to lobar 
intracerebral hemorrhage11. 
5. Diabetes mellitus 
Diabetes mellitus has a deteriorating effect on arterial blood vessels and 
it is a risk factor for ischemic stroke.DM increases the incidence of recurrent 
stroke12.Lacunar infarcts may be more common in diabetic patients13. 
6. Hypertension 
It is the treatable risk factor for stroke. Hypertension is commonly 
detected in stroke patients with age less than 55 years of age. Both systolic and 
diastolic BP is of importance as riskfactor14. A systolic BP increase of 20 
mmHg or a diastolic BP increase of 10 mmHg more than doubles the risk of 
stroke death 
7.Previous stroke 
Transient ischemic attack previous stroke is a powerful risk factor for 
new stroke. Also TIA increases the risk of subsequent risk of stroke in short 
and long term. Higher risk among those with diabetes, age 60years.longer 
duration of TIA, TIA with weakness or speech disturbances15. 
8. White matter disease       
 Both periventricular and subcortical white matter hyper intensities also 
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increase the risk of subsequent stroke, independently of the presence of silent 
brain infarcts16. 
9. Dyslipidemia 
Increased cholesterol levels are associated with carotid artery 
atherosclerosis and so increases the risk of cerebral infarcts caused by large 
vessel disease17. On the other hand low cholesterol level increases the risk of 
ICH18. Intense lowering of cholesterol level in stroke patients slightly increases 
the chance of ICH. 
10. Coagulation disorders  
Antiphospholipid antibody and lupus anticoagulant have been associated 
with ischaemic stroke. Coagulation disorder causing a venous thrombosis may 
give rise to paradoxical embolism through patent foramen ovale. 
11. Obstructive sleep apnea 
Obstructive sleep apnea may increase BP and cause stroke. Obstructive 
sleep apnea itself is an independent risk factor for stroke19. Possible 
mechanisms include hypercoagulability, atherosclerosis, decreased cerebral 
blood flow. Wake up stroke recently been linked to obstructive sleep apnea20. 
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12. Renal disease 
Renal disease increases the risk of stroke in individuals with known 
atherothrombotic disease. Micro albuminuria has been independently 
associated with stroke. 
13. Atrial fibrillation, cardiomyopathies, patent foramen ovale, valvular heart 
disease increases the risk of stroke. 
14. Lifestyle risk factors 
Smoking 
 Cigarette smoking increases the risk for ischemic stroke also increases 
the risk for ICH21. Both passive and active smoking increases the risk. 
Individuals who stop their smoking reduce their risk of stroke by up to 50%. 
Alcohol 
Excessive alcohol increases the stroke risk. Individuals who do not use 
any alcohol may have a slightly decreased stroke. It is possible that temporary 
heavy alcohol consumption increases the risk of immediate stroke"22. 
Diet 
 Fruit and vegetables may have a protective effect against both ischemic 
and hemorrhagic stroke. Individuals eating  three to five servings per day had a 
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relative risk of stroke of 0.89compared with those consuming less fruit and 
vegetables23. Fish consumption also reduces the risk of stroke. 
Physical activity 
 Physical activity decreases the risk of stroke compared with no physical 
activity24. Daily exercise of at least 30minutes decreases the relative risk of 
stroke to between 0.69 and0.74. Physical activity of at least 30 minutes three to 
five times per week has been recommended. Obesity: body mass index of 
25kg/m2 or more in men,30kg/m2or more in women increases the risk of 
ischaemic stroke25. Waist hip ratio also has been related to increased stroke 
risk. 
Hormonal therapy/OCP 
OCP increases the risk of ischemic stroke26. Hormone replacement 
therapy has also been related to increased risk of stroke . 
NEUTROPHILS 
Neutrophils are the most abundant type of granulocytes and the most 
abundant (40% to 70%) type of white blood cells in most mammals. They 
form an essential part of the innate immune system.  
Neutrophils are a type of phagocyte and are normally found in 
the bloodstream. During the acute phase of inflammation, particularly in 
bacterial infection and some cancers, neutrophils are one of the first-
 
 
24 
 
responders of inflammatory cells to migrate towards the site of inflammation. 
Neutrophils are recruited to the site of injury within minutes following trauma 
and are the hallmark of acute inflammation. 
The name neutrophil derives from staining characteristics on 
hematoxylin and eosin (h&E) histological or cytolocial preparations. Whereas 
basophilic white blood cells dark blue and eosinophilic white blood cells stain 
bright red, neutrophils stain a neutral pink. 
STRUCTURE 
 Neutrophil granulocytes have an average diameter of 12–
15 micrometers (µm) in peripheral blood smears. In suspension, human 
neutrophils have an average diameter of 8.85 µm. 
With the eosinophil and the basophil, they form the class 
of polymorphonuclear cells, named for the nucleus' multi lobulated shape. The 
nucleus has a characteristic lobed appearance, the separate lobes connected 
by chromatin. The nucleolus disappears as the neutrophil matures, which is 
something that happens in only a few other types of nucleated cells. In the 
cytoplasm, the Golgi apparatus is small, mitochondria and ribosomes are 
sparse, and the rough endoplasmic reticulum is absent. The cytoplasm also 
contains about 200 granules, of which a third are azurophilic.  
Neutrophils are sexually dimorphic. Neutrophils from women exhibit a 
small additional X chromosome structure, known as a "neutrophil drumstick". 
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Neutrophils will show increasing segmentation and normal neutrophil should 
have 3–5 segments. Hyper segmentation is not normal but occurs in some 
disorders such as vitamin B12 deficiency.   
NEUTROPHIL PLASMA MEMBRANE AND CYTOPLASM  
 The neutrophil plasma membrane contains several membrane channels, 
adhesive proteins, receptors for various ligands, ion pumps, and ectoenzymes. 
Neutrophils contain a complex cytoskeleton, which is responsible for 
chemotaxis, phagocytosis, and exocytosis. Some proteins that make up the 
cytoskeleton are actin, actin-binding protein, alpha-actinin,  gelsolin, profilin, 
myosin, tubulin, and tropomyosin. 
In addition to many components common to all cells, approximately 
45% of the neutrophil cytosolic protein is composed of migration inhibitory 
factor–related proteins (MRPs), such as MRP-8 and MRP-14.  
Neutrophils also release an assortment of proteins in three types of 
granules by a process called degranulation. The contents of these granules have 
antimicrobial properties, and help combat infection. 
SUBCELLULAR STRUCTURE OF NEUTROPHILS 
  Mature neutrophils contain 4 types of granules that are specialized 
lysosomes and serve as microbiocidal mediators designed to destroy microbial 
invaders. These granules have been classified as (1) primary or azurophil 
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granules, (2) secondary or specific granules, (3) tertiary or gelatinase granules, 
and (4) secretory vesicles.  
 
FIGURE 6 -  STRUCTURE OF NEUTROPHIL 
TABLE 1 : NEUTROPHIL GRANULES 
 
Granule type Protein 
Azurophilic granules      
(or primary granules ) 27 
Myeloperoxidase, bactericidal/permeability-
increasing protein (BPI), defensins, and the serine 
proteases neutrophil elastase and cathepsin G 
Specific granules                
 (or secondary granules ) 
Alkaline phosphatase, lysozyme, NADPH 
oxidase, collagenase, lactoferrin, histaminase and 
cathelicidin 
Tertiary granules  Cathepsin, gelatinase and collagenase 
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PRIMARY OR AZUROPHILIC GRANULES 
Primary or azurophilic granules contain the enzyme myeloperoxidase 
(MPO) , defensins, lysozyme, azurocidin, bacterial permeability–increasing 
protein (BPI), elastase, cathepsin G, proteinase, and esterase N. MPO, which 
constitutes approximately 5% of the dry weight of neutrophils, catalyzes the 
production of hypochlorite from chloride and hydrogen peroxide (H2 O2)27. 
Defensins are proteins that defend the body against a variety of bacteria, 
fungi, and viruses. Lysozyme is an enzyme that degrades bacterial 
peptidoglycans. Azurocidin demonstrates antibacterial activity and antifungal 
activity against Candida albicans. 
SECONDARY OR SPECIFIC GRANULES 
Secondary or specific granules are released into the extracellular space 
and contain apolactoferrin, vitamin B-12–binding protein, plasminogen 
activator, lysozyme, and collagenase. Apolactoferrin binds to iron, thereby 
depriving bacteria of the iron that is essential for cell growth. Collagenase 
degrades collagen and thus augments movement of neutrophils through 
collagen27. 
TERTIARY OR GELATINASE GRANULES 
Tertiary or gelatinase granules contain gelatinase, acetyltransferase, and 
lysozyme. Tertiary granules are up regulated to the surface with stimulation27. 
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DEVELOPMENT 
The first 3 morphologic stages in the development of mature neutrophils 
are capable of replication. Later stages of neutrophil development only undergo 
cell differentiation. The representative cells in the first 3 stages are 
myeloblasts, promyelocytes, and myelocytes. 
MYELOBLAST STAGE OF NEUTROPHIL DEVELOPMENT  
The myeloblast cell has a large nucleus which is round or oval, and has 
a small amount of cytoplasm with no granules. No condensation of chromatin 
is observed, and 2-5 nucleoli are present28.  
PROMYELOCYTE STAGE OF NEUTROPHIL DEVELOPMENT 
The promyelocyte cell is larger than the myeloblast. The nucleus is 
round or oval, and the nuclear chromatin is diffuse, as in the myeloblast. The 
azurophilic or primary granules appear at this stage, but the secondary granules 
are not yet present. The primary granules are budded off the concave surface of 
the Golgi complex28. 
MYELOCYTE STAGE OF NEUTROPHIL DEVELOPMENT 
In the myelocyte stage, the secondary granules appear which are smaller 
than the primary granules and stain heavily for glycoprotein. A pinkish ground-
glass background, which is the glycoprotein, is observed when the cell is 
stained. Secondary granules arise from the convex surface of the Golgi 
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complex. The myelocyte nucleus is eccentric and round or oval. The nuclear 
chromatin is coarse. The nucleoli are smaller and less prominent in the 
myelocyte stage when compared with the promyelocyte stage. 
Primary granule formation is limited to the promyelocyte .The number 
of primary granules decreases with each cell division and in mature 
neutrophils, the ratio of secondary granules to primary granules in humans is 
approximately 2-3:128. 
METAMYELOCYTE STAGE OF NEUTROPHIL DEVELOPMENT 
The metamyelocyte stage, is characterized by an indented or horseshoe-
shaped nucleus without nucleoli. The nuclear chromatin is dense, with 
considerable clumping along the nuclear membrane. The cytoplasm is filled 
with primary, secondary, and tertiary granules. In contrast to its precursors, the 
metamyelocyte stage is not capable of cell division28. 
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POLYMORPHONUCLEAR STAGE OF NEUTROPHIL 
DEVELOPMENT 
 
FIGURE 7 
In the last stage, band neutrophils undergo further condensation of the 
nuclear chromatin. The nucleus has a sausage shape with a uniform diameter 
throughout its length. The nucleus progressively begins to develop 1 or more 
constrictions, and, as the cell develops into the polymorphonuclear stage, the 
nucleus has 2 or more lobes connected with filamentous strands. In the 
polymorphonuclear stage, the cytoplasm appears faintly pink due to an 
abundance of specific granules28.  
FUNCTION 
The major role of neutrophils is to protect the body against infectious 
agents. The interaction of bacteria with antibodies and the complement system 
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results in the formation of various chemotactic agents. The initial response of 
the neutrophil is to migrate directionally toward the source of infection and 
adhere to the vascular endothelium and is mediated by adhesion molecules that 
are present on the neutrophils and the endothelial cells. The major types of 
adhesion molecules are the selectins, integrins, and immunoglobulin-type 
molecules. The selectins are the initial mediators of endothelial attachment, 
followed by the beta-2 integrins. Integrins are proteins on the leukocyte surface 
that, once activated, anchor the leukocyte to the endothelium. 
The next step is migration (diapedesis) through the vascular matrix. 
Following the increasing gradient of chemotaxins, neutrophils migrate toward 
the source of tissue irritation. During the migration, the presence of 
chemotactic agents primes the neutrophil for subsequent activation.  
Various chemoattractants, such as N -formyl peptides (eg, FMLP), 
C5a,leukotriene B4, and platelet-activating factor (PAF), are released in 
response to infection. 
The process of phagocytosis involves the projection of pseudopodia 
around a foreign particle, which then fuses with the neutrophil through 
invagination of the cell membrane, forming a phagosome. This process is more 
efficient if the organism is opsonized by antibodies or complement factors.   
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The contents of the neutrophil storage granules are discharged into this 
so-called biologic prison. Fusion of azurophil and specific granules with the 
phagosome follows phagolysosome formation.  
Bacterial cell death in the phagosome results from oxidative and 
nonoxidative mechanisms. 29Oxidative mechanisms can be mediated by MPO, 
or they can be independent from MPO. Following activation, a massive 
increase in the consumption of oxygen by the neutrophil occurs; this is called 
the respiratory burst. The respiratory burst results in the production of 
superoxide (O2-), H2 O2, and glucose oxidation via a hexose monophosphate 
shunt.  
NADPH is nicotinamide adenine dinucleotide phosphate; NADP+ is the 
oxidized form of NADPH, as shown in the following equation: 
2O2 + NADPH (NADPH oxidase) ↔ 2O2- + NADP+ + H+ 
Most O2- is rapidly converted to H2 O2, either spontaneously or by 
superoxide dismutase, as follows: 
2O2- + 2H+ ↔ O2 + H2 O2 
O2 and H2 O2 are not potent microbicides in themselves; rather, they 
help generate more potent oxidizing agents such as oxidized halogens and 
oxidizing radicals. MPO in the azurophilic granules is released into the 
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phagosome, which combines with H2 O2 and a halide (Cl- or Br-) to form 
oxidized halogen, which is a potent antimicrobial, as follows: 
Cl- + H2 O2 (MPO) ↔ H2 O + OCl- 
MPO-independent oxidative mechanisms of bacterial killing involve 
H2 O2, superoxide anion (O2), hydroxyl (OH) radical, and singlet oxygen 
(1O2 *).Oxygen-independent mechanisms play a role in bacterial killing in 
anaerobic conditions. These include acid, lysozyme, lactoferrin, defensins, BPI, 
azurocidin, serine proteinases, elastase, cathepsin G, and proteinase 3. Enzymes 
and oxidative agents are also released into the extracellular environment to kill 
invading bacteria. This process may result in tissue destruction. 
HYPERGLYCEMIA AND NEUTROPHIL FUNCTION 
Hyperglycemia decreases neutrophil activity, with an increased 
incidence of infection in patients with diabetes mellitus as the model of this 
occurrence. Elevated plasma glucose inhibits neutrophil degranulation as well 
as opsonization. There is evidence that shows hyperglycemia adversely affects 
neutrophil activity in bacterial and fungal infections. 
NEUTROPHIL EXTRACELLULAR TRAPS 
In 2004, Brinkmann and colleagues described a striking observation that 
activation of neutrophils causes the release of web-like structures of DNA; this 
represents a third mechanism for killing bacteria.29These neutrophil 
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extracellular traps (NETs) comprise a web of fibers composed 
of chromatin and serine proteases [27] that trap and kill extracellular microbes. It 
is suggested that NETs provide a high local concentration of antimicrobial 
components and bind, disarm, and kill microbes independent of phagocytic 
uptake. In addition to their possible antimicrobial properties, NETs may serve 
as a physical barrier that prevents further spread of pathogens. Trapping of 
bacteria may be a particularly important role for NETs in sepsis, where NETs 
are formed within blood vessels. Recently, NETs have been shown to play a 
role in inflammatory diseases, as NETs could be detected in preeclampsia, a 
pregnancy-related inflammatory disorder in which neutrophils are known to be 
activated. 
CLINICAL SIGNIFIANCE 
Absolute neutrophil count (ANC) is a measure of the number 
of neutrophil granulocytes present in the blood. The reference range for 
ANC in adults varies by study, but 1500 to 8000 cells per microliter is typical. 
An ANC less than 1500 cells/µL is defined as neutropenia and increases risk of 
infection. Neutropenia is the condition of a low ANC, and the most common 
condition where an ANC would be measured is in the setting of chemotherapy 
for cancer. ANC = WBC (cells/µL) X percent (PMNs + bands) ÷ 100 
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Risk Category ANC 
Mild ≥ 1000 to < 1500 cells/microL 
Moderate ≥ 500 to < 1000 cells/microL 
Severe < 500 cells/microL 
LYMPHOCYTE 
TYPES 
The three major types of lymphocyte are T cells, B cells and natural 
killer (NK) cells.  
T cells and B cells 
T cells (thymus cells) and B cells (bone marrow- or bursa-derived cells) 
are the major cellular components of the adaptive immune response. T cells are 
involved in cell-mediated immunity, whereas B cells are primarily responsible 
for humoral immunity (relating to antibodies). The function of T cells and B 
cells is to recognize specific “non-self” antigens, during a process known 
as antigen presentation. Once they have identified an invader, the cells generate 
specific responses that are tailored to maximally eliminate specific pathogens  
or pathogen-infected cells B cells. 
Natural killer cells 
NK cells are a part of the innate immune system and play a major role in 
defending the host from both tumors and virally infected cells. NK cells 
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distinguish infected cells and tumors from normal and uninfected cells by 
recognizing changes of a surface molecule called MHC (major 
histocompatibility complex) class I. NK cells are activated in response to a 
family of cytokines called interferons. Activated NK cells release cytotoxic 
(cell-killing) granules which then destroy the altered cells. They are named 
"natural killer cells" because they do not require prior activation in order to kill 
cells which are missing MHC class I. 
DEVELOPMENT 
The development of lymphocytes starts with the pluripotent 
hematopoietic stem cell 29. In embryogenesis these cells are found first in the 
yolk sac, thereafter in fetal liver, and finally in the bone marrow. In adults, 
hematopoietic stem cells occur almost uniquely in the bone marrow; The 
progeny of the pluripotent hematopoietic stem cell comprise cells committed to 
different lineages in the hematopoietic system  .A first differentiation involves 
the myeloid and lymphoid progenitor cell. The myeloid progenitor 
subsequently gives rise to precursors of erythrocytes, thrombocytes, 
granulocytes, and monocytes. The existence of a common lymphoid progenitor 
cell is still controversial, but there is evidence for the presence of progenitor 
cells that are committed to the T- or B-cell lineage. A cell surface marker that 
is widely used to identify and enrich hematopoietic stem and progenitor cells is 
the CD34 molecule, a molecule with a mucin-like structure and a possible 
ligand function for lectin-like adhesion molecules. 
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SPECIFICITY FOR ANTIGENS 
Rearrangement of genes encoding antigen receptors A major event in 
the differentiation of lineage-specific stem cells into mature T or B 
lymphocytes is the synthesis and surface expression of antigen receptors. This 
involves the generation of all potential specificities required for a functionally 
active immune system, namely, for T cells the α and ß chain of the T-cell 
receptor complex, and for B lymphocytes the light and heavy chains of the 
immunoglobulin molecule.  
SELECTION OF THE ANTIGEN-RECOGNITION REPERTOIRE  
Essentially, the specificity of the immune system is shaped after 
receptor gene rearrangement in the contributing T- and B-cells: the progeny of 
each distinct cell with a given specificity is considered to be a distinct clone, 
together constituting the whole repertoire of antigen recognition specificities. 
The only way to change specificity within a given clone is by somatic 
mutation, a process which occurs later in B-cell maturation30. 
 T-LYMPHOCYTE MATURATION IN THE THYMUS 
The thymus plays a pivotal role in shaping the T-cell repertoire, as 
exemplified by the absence of a functionally active T-lymphocyte system in 
individuals with a congenital absence of the thymus (humans with the Di-
George syndrome, rats and mice with the rnu or nu mutation). The thymus has 
a unique microenvironment of reticular epithelium which is not observed in 
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other lymphoid organs. Other cell populations contributing to T-cell 
development are dendritic cells and cells of the monocyte-macrophage cell 
lineage of bone-marrow origin which play a main role in antigen presentation 
and are mainly found in the medulla of the thymic lobes.   
Four main T-lymphocyte subsets, corresponding to various stages of 
development, are differentiated, based on their expression of CD3, CD4, CD8 
and CD25 receptor complex and are involved in antigen recognition in 
association with MHC class I or class II molecules on antigen-presenting 
cells30 
NEUTROPHIL TO LYMPHOCYTE RATIO 
The neutrophil to lymphocyte ratio (NLR), is a simple ratio that is 
obtained from the complete blood count of patient, which is found out by 
dividing absolute neutrophil count as numerator and absolute lymphocyte count 
as the denominator. So any condition which alters the counts will change the 
ratio, which can increase or decrease. The ratio indicates the inflammatory 
status of the individual, that is the cellular mediated inflammatory response. 
High value of the ratio indicates there is some response to inflammation 
happening in the body31. So many of the conditions NLR can vary and its value 
can be used in monitoring as a biomarker in  diabetes, obesity, metabolic 
syndromes, cardiovascular disease, renal failure, any chronic malnutrition 
states, cerebrovascular disease, alzheimer’s, COPD, and even in psychiatric 
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conditions like delirium etc. This parameter can also used in various cancers 
monitoring of therapy of drugs, prognosis of treatment with various therapies.  
The usefulness of NLR as an inflammatory marker can compared to 
other routinely used inflammatory markers like C-reactive protein interleukin-
1, tumor necrosis factor-α, ESR etc 31.Recently, it has been found that the use 
of NLR in various cancer prognostication including breast cancer, esophageal 
cancer, pancreatic cancer, colorectal cancers an elevated preoperative or 
pretreatment NLR, calculated from peripheral blood tests, was identified as an 
independent and readily available prognostic biomarker related to poor survival 
in numerous cancers, including colorectal cancer, breast cancer, gastric cancer 
and esophageal cancer, renal cell carcinomas and various study’s are 
undergoing in evaluating the same as inflammation is a basic pathogenesis 
happening in all cancers and in those states the NLR values are altered. 
The neutrophil–lymphocyte ratio (NLR) is an established marker of 
systemic inflammation, and has been recently reported as a predictor of 60 day 
mortality following AIS. NLR is an indicator of prognosis for cancer, cardiac 
disease, and sepsis and has been associated with both the presence and severity 
of coronary artery disease and metabolic syndrome. There is no widely used 
point of care biomarker proven to predict who will benefit from endovascular 
therapy, but white blood cell (WBC) counts are routinely obtained during acute 
stroke triage, making NLR a readily available biomarker. 
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It is well established that inflammation plays an important role in 
various atherosclerotic disorders 31. Elevated blood inflammatory markers such 
as high sensitivity C-reactive protein (hs-CRP) have been shown to be 
independent risk factors for cardiovascular disease and ischemic stroke.  
Recently, there have been reports of leukocytes having a similar role in 
ischemic events . Inflammatory cascade following acute ischemic stroke (AIS) 
is an important pathological process in damaged brain tissue . The 
inflammatory process in AIS involves cytokines and chemokines released from 
ischemic tissues, promoting the accumulation of leukocytes to the ischemic 
areas . Among circulating leukocytes, neutrophils have been regarded as crucial 
mediators of ischemic injury. 
Accumulated neutrophils release free oxygen radicals, various 
inflammatory cytokines, and neurotoxic substances, all of which cause cellular 
necrosis and apoptosis in ischemic tissues . Lymphocytes, a type of leukocyte, 
are also known to be involved in inflammatory responses to AIS . Low 
lymphocyte counts increase sympathetic activity and baseline cortisol levels, 
which can cause an increase in the production of inflammatory cytokines that 
aggravate ischemic injury . Therefore, increased total white blood cell (WBC) 
and leukocyte counts, and reduced lymphocyte counts are associated with poor 
outcomes in various cardiovascular diseases31.  
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METHODOLOGY 
 
SOURCE OF STUDY 
Data consist of primary data collected by the principal investigator 
directly from the cases of acute stroke admitted in the medical ward in 
Coimbatore Medical College Hospital. 
Design of study : Prospective study 
Period of study : ONE YEAR (2017 May to 2018 April) 
METHODOLOGY 
This is a prospective study of 100 cases managed for stroke in the 
medical ward of Coimbatore Medical College Hospital, Coimbatore for one 
year. 
INCLUSION CRITERIA 
1. All patients above 18yrs and having clinical and CT confirmed 
diagnosis of stroke. 
2. Patients presenting with TIA 
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EXCLUSION CRITERIA 
1. Patients below 18. 
2. Stroke due to trauma/neoplasm/active infection/immunosuppressive 
agents /hematological disease. 
3. Consent not given. 
4. Previous history of stroke and TIA. 
5. Patients with incomplete or lacking medical, demographic, clinical 
laboratory and radiological data.  
The data obtained were analysed using SPSS version software. Results 
were expressed in frequencies and percentages. 
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RESULTS 
 
TABLE 2 - OUTCOME OF STROKE 
 
OUTCOME NO OF PATIENTS PERCENTAGE 
DEAD 23 23% 
ALIVE 77 77% 
 
 
CHART 1 
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TABLE 3 - MORTALITY PATTERN 
 
MORTALITY NO OF PATIENTS PERCENTAGE 
AT HOSPITAL 13 57% 
AFTER ONE MONTH 10 43% 
 
 
CHART 2 
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TABLE 4 - AGE DISTRIBUTION 
 
AGE IN YRS NO OF PATIENTS PERCENTAGE 
LESS THAN 40 12 12% 
41-50 12 12% 
51-60 20 20% 
MORE THAN 60 56 56% 
 
 
CHART 3 
 
 
Out of 100 patients included in our study 56 patients were more than a 
age of 60 and 12 patients were less than a age of 40(12 %). 
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TABLE 5 - AGE WISE MORTALITY 
AGE IN YRS 
OUTCOME 
DEAD ALIVE 
LESS THAN 40 2 10 
41-50 2 10 
51-60 6 14 
MORE THAN 60 13 43 
KRUSKAL WALLIS TEST 
P VALUE - 0.776 
NON SIGNIFICANT 
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TABLE 6 -   SEX DISTRIBUTION 
SEX NO OF PATIENTS PERCENTAGE 
MALE 76 76% 
FEMALE 24 24% 
 
 
 
 
76 % of cases were male and 24% were females but this was not found to be 
statistically significant 
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TABLE 7 – SEX VS OUTCOME 
SEX 
OUTCOME 
DEAD ALIVE 
MALE 16 60 
FEMALE 7 17 
CHI SQUARE TEST 
P VALUE - 0.410 
NON SIGNIFICANT 
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TABLE 8 - TYPE OF STROKE 
 
TYPE OF STROKE NO OF PATIENTS PERCENTAGE 
ISCHEMIC 80 80% 
HEMORRHAGIC 20 20% 
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TABLE 9 - TYPE OF STROKE VS OUTCOME 
TYPE OF STROKE 
OUTCOME 
DEAD ALIVE 
ISCHEMIC 14 66 
HEMORRHAGIC 9 11 
CHI SQUARE TEST 
P VALUE - 0.009 
SIGNIFICANT 
 
 
 
Ischemic stroke contributed 80% in comparison to hemorrhagic stroke 
in our study. The mortality percentage in ischemic stroke is 17.5% when 
compared to hemorrhagic stroke in which the mortality percentage is 45% 
which has a significant p value. 
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TABLE 10 - RISK FACTOR PROFILE 
RISK FACTORS NO OF CASES PERCENTAGE P value 
SMOKING 35 35 0.980 
DIABETES 40 40 0.561 
HYPERTENSION 43 43 0.136 
DYSLIPIDEMIA 30 30 0.270 
CORONARY ARTERY 
DISEASE 
12 12 0.861 
 
TABLE 11 -  HISTORY OF SMOKING 
SMOKING H/O NO OF PATIENTS PERCENTAGE 
PRESENT 35 35% 
ABSENT 65 65% 
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TABLE 12 - H/O SMOKING VS OUTCOME 
SMOKING H/O 
OUTCOME 
DEAD ALIVE 
PRESENT 10 25 
ABSENT 15 50 
CHI SQUARE TEST 
P VALUE - 0.980 
NON SIGNIFICANT 
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TABLE 13 -  H/O DIABETES MELLITUS IN STROKE 
 
DIABETES NO OF PATIENTS PERCENTAGE 
PRESENT 40 40% 
ABSENT 60 60% 
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TABLE 14 -  DIABETES VS OUTCOME 
DIABETES 
OUTCOME 
DEAD ALIVE 
PRESENT 8 32 
ABSENT 15 45 
CHI SQUARE TEST 
P VALUE - 0.561 
NON SIGNIFICANT 
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TABLE 15 -  H/O HYPERTENSION IN STROKE 
 
HYPERTENSION NO OF PATIENTS PERCENTAGE 
PRESENT 43 43% 
ABSENT 57 57% 
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TABLE 16 -  OUTCOME IN HYPERTENSIVES VS NON 
HYPERTENSIVES 
HYPERTENSION 
OUTCOME 
DEAD ALIVE 
PRESENT 13 30 
ABSENT 10 47 
CHI SQUARE TEST 
P VALUE - 0.136 
NON SIGNIFICANT 
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TABLE 17- SYSTOLIC BP IN STROKE PATIENTS 
SYSTOLIC BP NO OF PATIENTS PERCENTAGE 
> 140 mmHg 64 64% 
< 140 mmHg 36 36% 
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                 TABLE 18 - MEAN SYSTOLIC BP VS OUTCOME 
OUTCOME 
SYSTOLIC BP 
MEAN SD 
DEAD 164.43 25.88 
ALIVE 153.5 19.91 
UNPAIRED T TEST 
P VALUE - 0.034 
SIGNIFICANT 
 
 
 
The average systolic blood pressure of patients who are expired is 
164.43 +/-25.88 when compared to survivors which is 153.5+/- 19.91. 
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TABLE 19 -  DIASTOLIC BP IN STROKE PATIENTS 
 
DIASTOLIC BP NO OF PATIENTS PERCENTAGE 
> 90 mmHg 40 40% 
< 90 mmHg 60 60% 
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TABLE 20 -  MEAN DIASTOLIC BP VS OUTCOME 
OUTCOME 
DIASTOLIC BP 
MEAN SD 
DEAD 95.91 12.58 
ALIVE 92.36 8.94 
UNPAIRED T TEST 
P VALUE - 0.134 
NON SIGNIFICANT 
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TABLE 21- CORONARY ARTERY DISEASE IN STROKE 
CAD NO OF PATIENTS PERCENTAGE 
PRESENT 12 12% 
ABSENT 88 88% 
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TABLE 22 -  H/O CAD VS OUTCOME 
CAD 
OUTCOME 
DEAD ALIVE 
PRESENT 3 9 
ABSENT 20 68 
CHI SQUARE TEST 
P VALUE - 0.861 
NON SIGNIFICANT 
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TABLE 23 - DYSLIPIDEMIA IN STROKE PATIENTS 
DYSLIPIDEMIA NO OF PATIENTS PERCENTAGE 
PRESENT 30 30% 
ABSENT 70 70% 
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TABLE 24 -  DYSLIPIDEMIA VS STROKE OUTCOME 
DYSLIPIDEMIA 
OUTCOME 
DEAD ALIVE 
PRESENT 9 21 
ABSENT 14 56 
CHI SQUARE TEST 
P VALUE - 0.270 
NON SIGNIFICANT 
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TABLE 25 -  GCS SCORE IN STROKE PATIENTS 
 
GCS SCORE NO OF PATIENTS PERCENTAGE 
MILD (12-15) 6 6% 
MODERATE(9-12) 64 64% 
SEVERE (<9) 30 30% 
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TABLE 26 -  GCS SCORE VS OUTCOME 
GCS SCORE 
OUTCOME 
DEAD ALIVE 
MILD (12-15) 0 6 
MODERATE(9-12) 0 64 
SEVERE (<9) 23 7 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
 
 
Out of 30 patients who had low GCS score <9 , 23 were expired which gives  
direct interpretation that low GCS leads to ,mortality and statistically 
significant p value of 0.001. 
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TABLE 27 - MEAN TIME DURATION VS OUTCOME 
OUTCOME 
TIME DURATION 
MEAN SD 
DEAD 15.65 3.2 
ALIVE 10.35 2.87 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
 
 
The survival rate of patients increases as they arrived early to the 
hospital within a mean time of 10.35 + 2.87hrs when compared to non 
survivors who presented  with an average  time duration of 15.65 + 3.2hrs 
which when analysed statistically using unpaired t test has got a significant p 
value of 0.001. 
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TABLE 28 - DURATION OF HOSPITAL STAY 
OUTCOME 
DURATION OF HOSPITAL STAY 
MEAN SD 
DEAD 4.43 2.57 
ALIVE 6.78 0.98 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 29 - TOTAL COUNT IN STROKE PATIENTS 
OUTCOME 
TOTAL COUNT 
MEAN SD 
DEAD 9695.48 650.24 
ALIVE 7184.96 1029.87 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
 
 
 
In our study among the non survivor patients the average total count was 
9695.48 + 650.24 in contrast to survivors who has total count of 7184.96 + 
1029.87.The mortality increases in the patients who had higher total count 
value at the time of presentation which has got a significant p value of 0.001 
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TABLE 30 - NEUTROPHIL LYMPHOCYTE RATIO 
OUTCOME 
NEUTROPHIL LYMPHOCYTE RATIO 
MEAN SD 
DEAD 12.86 1.56 
ALIVE 6.32 1.38 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
 
 
The main objective of our study was to find a correlation between NLR and its 
association with stroke outcome which when analysed statistically  found that 
higher the NLR higher the mortality(p value 0.001). 
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TABLE 31 - SCANDINAVIAN STROKE SCORE 
OUTCOME 
SCANDINAVIAN STROKE SCORE 
MEAN SD 
DEAD 8.96 2.36 
ALIVE 34.95 6.58 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 32 - GCS SCORE VS OUTCOME 
OUTCOME 
GLASGOW COMA SCALE 
MEAN SD 
DEAD 4.87 1.91 
ALIVE 10.38 1.49 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 33 - SCANDINAVIAN STROKE SCORE VS  
MORTALITY AT HOSPITAL 
MORTALITY AT HOSPITAL 
SCANDINAVIAN STROKE SCORE 
MEAN SD 
YES 7.38 1.44 
NO 32.2 9.87 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 34 - SCANDINAVIAN STROKE SCORE VS OUTCOME  
AT 1 MONTH 
MORTALITY AFTER 1 MONTH 
SCANDINAVIAN STROKE SCORE 
MEAN SD 
YES 11 1.63 
NO 30.97 11.49 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 35 - GCS VS MORTALITY AT HOSPITAL 
MORTALITY AT HOSPITAL 
GLASGOW COMA SCALE 
MEAN SD 
YES 3.46 0.72 
NO 9.95 1.88 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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CHART 34 GCS VS MORTALITY AT HOSPITAL
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TABLE 36 - GCS SCORE VS MORTALITY AFTER ONE MONTH 
MORTALITY AFTER 1 MONTH 
GLASGOW COMA SCALE 
MEAN SD 
YES 6.7 1.25 
NO 9.38 2.82 
UNPAIRED T TEST 
P VALUE - 0.004 
SIGNIFICANT 
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TABLE 37 - MEAN NLR VS MORTALITY AT HOSPITAL 
MORTALITY AT HOSPITAL 
NEUTROPHIL LYMPHOCYTE RATIO 
MEAN SD 
YES 12.84 1.96 
NO 7.67 2.49 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 38 - MEAN NLR VS MORTALITY AFTER 1 MONTH 
MORTALITY AFTER 1 
MONTH 
NEUTROPHIL LYMPHOCYTE 
RATIO 
MEAN SD 
YES 12.88 0.9 
NO 7.26 2.73 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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CHART 37 MEAN NLR VS MORTALITY AFTER 1 MONTH
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DISCUSSION 
This study is a prospective study conducted in Coimbatore Medical 
College from 2017  May to 2018 April in which neutrophil lymphocyte ratio 
was calculated for 100 stroke patients admitted during the above period and it 
is correlated with in hospital and 30 days mortality.  
Inflammation plays an important role in the development of ischemic 
stroke .Lymphocytes has been shown to potentiate cerebral inflammation and 
brain injury in both ischemic and hemorrhagic stroke . Neutrophil lymphocyte 
ratio reflect the immune status and the degree of inflammatory infiltration. 
Neutrophil lymphocyte ratio is a time dependent variable in patients with 
stroke. Neutrophil lymphocyte ratio increases with time in first few days.  
 Many previous studies suggested that neutrophil lymphocyte ratio 
increases within 12 hour after onset of stroke and reaches peak value on the 
second day. Balestrino et al found that higher leucocyte and neutrophil 
lymphocyte ratio are observed during the acute period of stroke and these 
values are correlated with poor prognosis. Christensen et al also found similar 
results .We also found significant higher neutrophil lymphocyte ratio in both 
ischemic and hemorrhagic stroke patients and it directly correlates with the 
short term mortality. 
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SUMMARY 
 Out of 100 patients who are included in our study 23 patients  expired . 
 Among 23 patients, 13 expired during the hospital stay 10 patients 
expired after discharge at home. 
 Male patients were around 76% and female patients around 24% in 
which 16 male patients expired when compared to female patients in 
which 7 expired. 
 Among 100 stroke patients 80 patients had ischemic stroke and 20 
patients had hemorrhagic stroke and the mortality rate when compared 
was found to be high in hemorrhagic stroke patients . 
 In 100 stroke patients in our study, 35 patients were smokers which is an 
important risk factor but doesn’t have significant statistical value in our 
study. 
 Diabetes and Hypertension the two most important non communicable 
diseases present in our country was found in 40 and 43 patients 
respectively in our study. 
 Young stroke contributed 12% of our study population. 
 The average systolic blood pressure of the patients who succumbed was 
164.43 + 25.88. 
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 12 patients in our study had previous history of coronary artery disease 
out of which 3 expired. 
 The average GCS score of the patients who expired were less than 9 
irrespective of the stroke type and also had significant p value . 
 Patients who presented early to the medical care had better survival 
compared to those patients who presented late which was  found to be 
statistically significant. 
 The mean duration of hospital stay of survivors is 4.43 + 2.57 days 
compared to non survivors in which the stay is 6.78 + 0.98 . 
 The average total count of expired patients is 9695 + 650 which directly 
gives us an inference that inflammation plays a vital role in stroke 
outcome. 
 The average Neutrophil lymphocyte ratio of patients who expired in our 
study is 12.86+/-1.56 which is consistent with other studies in both 
ischemic and hemorrhagic stroke. When the results were analysed using 
unpaired t test significant p value was obtained (less than 0.001). 
 GCS and SSS both were used to assess the severity of the stroke in our 
study. 
 Patients who had low GCS and high SSS succumbed to the disease. 
 NLR ratio was high in patients who expired both in hospital and in the 
home. 
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LIMITATIONS OF THE STUDY 
 There were only 100 patients included in our study which is of small 
sample size. 
 Inflammatory process was a relatively complex and we are unable to 
measure other inflammatory markers such as interleukin 6, tumour 
necrosis factor etc in our hospital because of lack of facilities. If NLR 
could be correlated with these inflammatory markers the results may be 
better. 
 Accurately determining the optimal time to test NLR in stroke patients 
needs additional research. 
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CONCLUSION 
 
1. Immune dysregulation influences stroke outcome in which NLR may be 
used as a simple and easy biomarker to predict short term prognosis in both 
ischemic and hemorrhagic stroke. 
2. This study find a statistically significant correlation between NLR and 
stroke outcome. 
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APPENDIX I- PROFORMA 
A STUDY ON THE NEUTROPHIL LYMPHOCYTE RATIO 
AS AN EARLY PREDICTOR OF SHORT TERM 
MORTALITY IN PATIENTS WITH STROKE 
 
NAME: AGE/SEX: 
I.P.NO:                                                                            UNIT: 
OCCUPATION:                                                              ADDRESS: 
Complaints with duration :  
History of Present Illness :  
1. Weakness of limbs : Present / Absent  
If Present  
a. Limbs involved : Upper limb : Right / Left Lower Limb : Right / Left  
b. Mode of onset : Sudden / Insidious / Slow  
c. Duration :  d. Progression  :  
2. Weakness of Face : Present / Absent 
If Present :  
a. Part of face involved : Upper / Lower 
b. Deviation of angle of mouth : Right side / Left side  
c. Difficulty in closing eyes : Present / Absent 
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3. Level of Consciousness Alert / Drowsy / Unconscious  
4. Speech disturbances : Present / Absent  
If Present :  
a. Slurring of speech : Present / Absent  
b. Comprehension : Normal / Abnormal  
5. History suggestive of Cranial nerve palsy :  
H/o Blurring of Vision : Present / Absent  
Diplopia : Present / Absent  
Dysphagia : Present / Absent  
Nasal regurgitation : Present / Absent  
6. H/o Sensory disturbances : Present / Absent  
PAST HISTORY  
1. History of previous cerebrovascular accidents : Yes / No  
2. History of TIA : Yes / No  
3. History of IHD : Yes / No  
4. History of Hypertension : Yes / No  
5. History of  diabetes mellitus : Yes / No  
6. History of RHD : Yes / No  
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Personal History :  
Smoking : Yes / No  
Alcohol intake : Yes / No  
General Physical Examination : 
Vital signs : Pulse : B.P. : RR :  
CNS examination  
CVS examination  
Respiratory system examination  
Abdomen examination 
Investigation :  
CBC  
Lipid profile  
Blood Glucose : FBS PPBS  
ECG  
C.T. Scan  
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1 54 M ISCHEMIC 10 YES         130/80 10 5 4000 4.94 32     
2 58 M ISCHEMIC 11 YES         140/90 8 7 5550 5.32 24     
3 65 M ISCHEMIC 13           130/90 9 6 6500 5.11 27     
4 89 M ISCHEMIC 18 YES     YES YES 140/80 3 2 9500 10.23 6 YES   
5 48 M HEMORRHAGE 12     YES     190/100 13 4 4600 6.22 45     
6 66 F ISCHEMIC 8         YES 130/90 11 5 5500 5.88 38     
7 61 M ISCHEMIC 9     YES     160/90 10 7 7800 4.44 30     
8 32 M ISCHEMIC 10 YES       YES 130/90 12 6 6700 6.08 42     
9 49 M ISCHEMIC 11   YES       140/90 9 8 6660 5.77 28     
10 51 F HEMORRHAGE 16     YES     200/110 4 2 9800 11.48 8 YES   
11 59 M ISCHEMIC 7   YES YES     156/80 9 8 5500 4.98 28     
12 63 F ISCHEMIC 11   YES YES   YES 170/90 10 5 5400 5.56 30     
13 50 M ISCHEMIC 21 YES YES       140/90 7 8 9700 12.33 11   YES 
14 60 M ISCHEMIC 8 YES   YES     166/84 11 5 6600 6.32 34     
15 70 M HEMORRHAGE 9     YES     180/120 12 7 5600 5.98 38     
16 35 M ISCHEMIC 11 YES       YES 130/80 9 8 5490 5.88 28     
17 61 M ISCHEMIC 12   YES       140/80 9 6 6780 7.32 26     
18 71 F ISCHEMIC 16   YES       130/90 11 7 5670 7.89 35     
19 73 M ISCHEMIC 13   YES       140/90 13 5 6780 4.34 46     
20 68 M HEMORRHAGE 17 YES   YES YES YES 190/110 5 2 9990 10.55 8 YES   
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21 63 M ISCHEMIC 8     YES     170/100 14 6 7800 6.55 47     
22 70 M ISCHEMIC 9   YES YES     164/98 13 7 7600 5.87 43     
23 62 M ISCHEMIC 10 YES         130/90 11 8 7890 6.77 38     
24 33 F ISCHEMIC 13   YES YES YES YES 180/96 12 6 8900 7.21 47     
25 65 M HEMORRHAGE 16 YES   YES     200/110 12 5 8956 7.86 44     
26 57 M ISCHEMIC 19 YES YES       140/90 3 2 9870 13.55 9 YES   
27 45 M ISCHEMIC 7   YES       130/90 8 6 6890 6.65 29     
28 53 M ISCHEMIC 8 YES   YES   YES 184/100 9 6 6780 7.2 30     
29 66 M ISCHEMIC 9           140/90 11 7 6570 4.98 36     
30 62 F HEMORRHAGE 12     YES   YES 210/120 3 3 9990 12.87 6 YES   
31 71 M ISCHEMIC 14 YES         130/90 12 6 5670 7.44 44     
32 35 M ISCHEMIC 8 YES       YES 140/90 11 8 6780 8.54 38     
33 74 M ISCHEMIC 9   YES YES     174/88 9 7 7890 7.88 31     
34 62 M ISCHEMIC 18   YES   YES YES 130/80 7 6 9790 13.98 12   YES 
35 58 F HEMORRHAGE 9     YES     170/110 10 8 5670 6.88 37     
36 67 F ISCHEMIC 7   YES YES     168/90 13 7 5670 5.76 47     
37 75 M ISCHEMIC 12 YES         140/90 12 6 4560 6.77 42     
38 56 M ISCHEMIC 11 YES       YES 150/90 13 8 5670 8.32 48     
39 55 M ISCHEMIC 8   YES       140/80 9 7 6780 3.88 32     
40 31 M HEMORRHAGE 12 YES   YES   YES 180/100 5 2 8900 11.12 10 YES   
41 60 M ISCHEMIC 11   YES       150/80 8 8 8976 12.65 12   YES 
42 63 F ISCHEMIC 14     YES YES YES 164/86 9 7 7890 5.76 26     
43 68 M ISCHEMIC 9           140/90 10 6 7856 6.34 29     
44 70 M ISCHEMIC 8 YES YES YES     172/94 11 7 4570 5.32 40     
45 74 F HEMORRHAGE 14   YES YES     180/110 11 6 7680 4.23 39     
46 72 M ISCHEMIC 12 YES         150/90 11 7 8900 5.66 36     
47 63 M ISCHEMIC 18   YES       140/90 4 8 8970 13.09 8   YES 
48 35 F ISCHEMIC 8   YES YES     150/96 8 6 6700 8.88 28     
49 71 M ISCHEMIC 15 YES   YES     168/82 3 3 9800 16.04 9 YES   
50 74 F HEMORRHAGE 12     NO   YES 160/100 3 2 8900 15.88 6 YES   
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51 69 M ISCHEMIC 8 YES YES       150/90 12 8 8970 4.11 44     
52 62 M ISCHEMIC 11 YES         140/80 6 6 9070 12.11 11   YES 
53 58 M ISCHEMIC 5       YES YES 150/80 11 7 9000 5.33 40     
54 53 F ISCHEMIC 5   YES       150/90 10 8 9800 6.22 38     
55 55 M HEMORRHAGE 4   YES YES     190/100 10 6 8900 7.18 37     
56 30 M ISCHEMIC 8 YES   YES   YES 190/88 9 7 10800 5.88 35     
57 82 M ISCHEMIC 7   YES       140/90 8 7 5670 7.65 28     
58 72 M ISCHEMIC 11   YES     YES 140/80 8 6 6780 7.43 24     
59 74 M ISCHEMIC 15           130/80 12 7 7800 5.59 38     
60 80 F HEMORRHAGE 19     YES     200/110 3 2 9990 11.28 8 YES   
61 61 M ISCHEMIC 14           130/90 12 8 4570 8.88 40     
62 69 M ISCHEMIC 12 YES     YES YES 130/90 11 7 5670 4.16 36     
63 75 M ISCHEMIC 20 YES YES YES     170/88 3 2 10800 14.78 5 YES   
64 33 F ISCHEMIC 12           130/90 12 6 5600 6.53 38     
65 67 F HEMORRHAGE 13     YES     180/120 10 6 7800 6.74 36     
66 60 F ISCHEMIC 9   YES YES     174/86 9 6 8900 5.22 28     
67 72 M ISCHEMIC 7           140/80 9 7 8970 8.18 26     
68 71 M ISCHEMIC 8 YES YES       146/98 9 8 5600 5.76 30     
69 78 M ISCHEMIC 13 YES         150/84 11 7 7800 4.33 40     
70 59 M HEMORRHAGE 17     YES   YES 190/110 3 3 9800 14.39 7 YES   
71 54 M ISCHEMIC 16           146/86 8 7 8900 12.86 13   YES 
72 34 F ISCHEMIC 12   YES YES     190/90 12 6 7800 7.55 38     
73 80 M ISCHEMIC 11           134/86 12 8 6700 6.88 40     
74 83 M ISCHEMIC 9         YES 136/84 9 7 5670 8.44 28     
75 74 M HEMORRHAGE 7 YES   YES     200/110 10 6 6780 6.32 32     
76 76 M ISCHEMIC 8 YES YES       146/96 9 6 7800 7.12 30     
77 70 M ISCHEMIC 11   YES YES     150/96 7 8 8970 13.33 10   YES 
78 80 F ISCHEMIC 16   YES   YES YES 146/96 11 7 7800 7.79 40     
79 64 M ISCHEMIC 17   YES       144/96 9 8 10800 6.84 30     
80 29 F HEMORRHAGE 11     YES   YES 210/120 8 7 10900 14.08 13   YES 
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81 88 M ISCHEMIC 12   YES       144/84 11 8 7800 3.23 38     
82 78 M ISCHEMIC 15   YES     YES 150/96 11 6 6700 4.55 34     
83 64 M ISCHEMIC 12       YES YES 146/96 9 7 10900 8.14 29     
84 84 F ISCHEMIC 16     YES     168/94 3 2 10400 11.98 7 YES   
85 75 M HEMORRHAGE 7   YES YES     170/110 12 8 7800 4.66 47     
86 60 M ISCHEMIC 8           146/96 10 7 5000 6.23 36     
87 87 M ISCHEMIC 9 YES         134/96 9 9 6780 4.78 30     
88 35 M ISCHEMIC 13 YES YES YES   YES 190/106 11 7 7800 3.92 44     
89 49 M ISCHEMIC 17         YES 134/94 6 6 9090 13.34 9   YES 
90 70 F HEMORRHAGE 15   YES YES     180/100 6 8 9990 11.06 11   YES 
91 47 M ISCHEMIC 9     YES     148/94 10 7 7800 5.34 32     
92 57 M ISCHEMIC 8 YES     YES YES 158/90 9 8 8900 5.69 26     
93 44 M ISCHEMIC 12 YES         150/84 9 7 7800 6.22 28     
94 50 M ISCHEMIC 15   YES       146/88 11 6 6790 5.95 35     
95 48 F HEMORRHAGE 9     YES     180/110 8 7 10800 7.82 26     
96 35 F ISCHEMIC 12     YES     150/90 11 8 5600 8.43 33     
97 46 M ISCHEMIC 14       YES YES 134/96 9 7 8900 8.54 28     
98 55 M ISCHEMIC 18     YES     146/96 4 3 10900 12.86 7 YES   
99 49 M ISCHEMIC 8 YES YES YES     160/90 11 8 11000 7.14 40     
100 43 M HEMORRHAGE 9 YES   NO YES YES 170/90 8 7 8090 9.22 27     
 
